Business Description
X4 Pharmaceuticals Inc
NAICS : 325412
SIC : 2836
ISIN : US0428731097
Description
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.96 | |||||
| Equity-to-Asset | 0.35 | |||||
| Debt-to-Equity | 1.14 | |||||
| Debt-to-EBITDA | -0.61 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 43.3 | |||||
| 3-Year EPS without NRI Growth Rate | 41.9 | |||||
| 3-Year FCF Growth Rate | 43.4 | |||||
| 3-Year Book Growth Rate | -59.1 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.39 | |||||
| 9-Day RSI | 39.94 | |||||
| 14-Day RSI | 44.14 | |||||
| 6-1 Month Momentum % | 91.04 | |||||
| 12-1 Month Momentum % | -3.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.34 | |||||
| Quick Ratio | 5.34 | |||||
| Cash Ratio | 5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -117.4 | |||||
| Shareholder Yield % | -41.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -162.15 | |||||
| ROA % | -65.36 | |||||
| ROIC % | -322 | |||||
| ROC (Joel Greenblatt) % | -1298.39 | |||||
| ROCE % | -72.03 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.76 | |||||
| Price-to-Tangible-Book | 5.83 | |||||
| EV-to-EBIT | -1.4 | |||||
| EV-to-EBITDA | -1.41 | |||||
| EV-to-Forward-Revenue | 4.36 | |||||
| EV-to-FCF | -1.39 | |||||
| Price-to-Net-Current-Asset-Value | 7.77 | |||||
| Price-to-Net-Cash | 10.59 | |||||
| Earnings Yield (Greenblatt) % | -71.43 | |||||
| FCF Yield % | -49.36 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:XFOR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
X4 Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.59 | ||
| Beta | 0.71 | ||
| Volatility % | 103.94 | ||
| 14-Day RSI | 44.14 | ||
| 14-Day ATR ($) | 0.12961 | ||
| 20-Day SMA ($) | 1.304 | ||
| 12-1 Month Momentum % | -3.33 | ||
| 52-Week Range ($) | 0.5723 - 2.575 | ||
| Shares Outstanding (Mil) | 167.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
X4 Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
X4 Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
X4 Pharmaceuticals Inc Frequently Asked Questions
What is X4 Pharmaceuticals Inc(XFOR)'s stock price today?
The current price of XFOR is $1.17. The 52 week high of XFOR is $2.58 and 52 week low is $0.57.
When is next earnings date of X4 Pharmaceuticals Inc(XFOR)?
The next earnings date of X4 Pharmaceuticals Inc(XFOR) is 2024-05-03 Est..
Does X4 Pharmaceuticals Inc(XFOR) pay dividends? If so, how much?
X4 Pharmaceuticals Inc(XFOR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers